print

David G. Hicks, M.D.

Professor of Pathology and Laboratory Medicine

Surgical Pathology
Bone, Soft Tissue and Breast Diseases

URMC Labs
601 Elmwood Ave., Rm G-5320A
Rochester, NY 14642-8626
Tel: (585) 275-3191
Fax: (585) 273-3637

David_Hicks@urmc.rochester.edu
send e-mail

Director of Surgical Pathology. Dr. Hicks' innovative approaches to improving efficiency and quality in surgical pathology have been highlighted in publications and invited lectures sponsored by national pathology organizations. His organizational interests are in the development of a subspecialty-based surgical pathology system, combining disease-specific diagnostic and prognostic expertise with translational research based on organ systems and disease categories.

Qualifications

M.D. University of Rochester, 1984
Intern, Medicine, Hospital of the University of Pennsylvania, 1984-85
Resident, Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, 1985-89
Board Certification, American Board of Pathology (Anatomic Pathology), 1990

Professional Activities

Stowell-Orbison Award, US and Canadian Academy of Pathology, 1989
Arthur Purdy Stout Award, US and Canadian Academic of Pathology, 1991
Kappa Delta Elizabeth Winston Lanier Award for Outstanding Orthopaedic Research, American Academy of Orthopaedic Surgeons, 1995
Andrew W. Mellon Dean's Teaching Scholar, University of Rochester, 1996-99
John Beach Hazard Distinguished Teaching Award, Cleveland Clinic Foundation, 2002
Dr. Edith E. Sproul Teaching Award, Roswell Park Cancer Institute, 2006

Archives of Pathology and Laboratory Medicine, Editorial Board

Biotechnic & Histochemistry, Editorial Board

Applied Immunohistochemistry & Molecular Morphology, Editorial Board

Research Overview

Dr. Hicks' first research interest was in bone pathology. He received NIH funding to study the effects of lead on the epiphyseal plate, and collaborated on related studies with faculty in the Department of Orthopaedics at the University of Rochester. He published extensively on metabolic and neoplastic bone disorders. While Director of Surgical Pathology and Co-director of the Morphologic Molecular Pathology translation research resource at the Cleveland Clinic, he expanded his interests in breast pathology, with particular focus on prognostic molecular markers in breast cancer and development of advanced tissue-based diagnostic techniques.

Publications

Kulkarni S, Hicks DG, Watroba N, Murekeyisoni C, Hwang H, Khoury T, Beck RA, Ring BZ, Estopinal N, Schreeder M, Seitz RS, Ross DT.  TLE3 as a candidate biomarker of response to taxane therapy.  Breast Cancer Res Treat. 2009 March 23;11(2):R17.

Zhang Y, Sieuwerts AM, McGreevy M, Casey G, Cufer T, Paradiso A, Harbeck N, Span PN, Hicks DG, Crowe J, Tubbs RR, Budd GT, Lyons J, Sweep CGJ, Schmitt M, Schittulli F, Golouh R, Talantov D, Wang Y, Foekens JA.  The 76-gene signature defines high risk patients that benefit from adjuvant tamoxifen therapy.  Breast Cancer Res Treat. 2009 July;116(2):303-309.

Yaziji H, Taylor CR, Goldstein N, Dabbs D, Hammond E, Hewlett B, Floyd A, Barry A, Martin A, Badve S, Baehner F, Cartun R, Eisen R, Swanson P, Hewitt S, Vyberg M, Hicks DG.  Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry.  Appl Immunohistochem Mol Morphol. 2008 December;16(6):513-520.

Wei B, Wang J, Bourne P, Yang Q, Hicks D, Bu H, Tang P. Bone metastasis is strongly associated with ER positive/PR negative breast carcinomas.  Hum Pathol 2008 December;39(12):1809-15.

Hicks DG, Hammond E, Kulkarni S.  The role of the indispensable surgical pathologist in treatment planning for breast cancer.  Arch Pathol Lab Med. 2008 August;132(8):1226-1227.

Hicks DG, Kulkarni S.  Trastuzumab as adjuvant therapy for early breast cancer: The importance of accurate HER2 testing.  Arch Pathol Lab Med. 2008 June;132(6):1008-1015.

Kulkarni S, Hicks DG.  HER2-positive early breast cancer and trastuzumab: a surgeon’s perspective.  Ann Surg Oncol. 2008 June;15(6):1677-1688.

Hicks DG, Kulkarni S.  HER2-positive breast cancer: review of biologic relevance and optimal use of diagnostic tools.  Am J Clin Pathol. 2008 February;129(6):263-273.

Sossey-Alaoui K, Safina A, Li X, Vaughan MM, Hicks DG, Bakin AV, Cowell JK.  Down-regulation of WAVE3, a metastasis promoter gene, inhibits invasion and metastasis of breast cancer cells.  Am J Pathol. 2007 June;170(6):2112-2121.

Goldstein NS, Hewitt SM, Taylor CR, Yaziji H, Hicks DG.  Recommendations for improved standarization of immunohistochemistry.  Appl Immunohistochem Mol Morphol. 2007 June;159(2):124-133.

Leitman SA, Prescott NL, Hicks DG, Westra WK, Levine MA.  SH3BP2 is rarely mutated in exon 9 in giant cell lesion outside cherubism. Clin Orthop Relat Res. 2007 June;459:22-27.

Powell WC, Hicks DG, Prescott N, Tarr SM, Laniauskas S, Williams T, Short S, Pettay J, Nagel RN, Dabbs DJ, Scott KM, Brown RW, Grogan T, Roche PC, Tubbs R.  A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 statusin breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH) and interlaboratory reproducibility.  Appl Immunohistochem Mol Morphol. 2007 March;15(1):94-102.

Ghadersohi A, Pan D, Fayazi Z, Hicks DG, Winston JS, Li F.  Prostate-derived Ets transcription factor (PDEF) down regulates survivin expression and inhibits breast cancer cell growth in vitro and xenograft tumor formation in vivo.  Breast Cancer Res Treat. 2007 March;102(1):19-30.

Short SM, Yoder BJ, Tarr SM, Prescott NL, Laniauskas S, Coleman KA, Downs-Kelly E, Pettay JD, Choueiri TK, Crowe JP, Tubbs RR, Budd TG, Hicks DG.  The expression of the cytoskeletal focal adhesion protein paxillin in breast cancer correlates with HER2 overexpression and may help predict response to chemotherapy: A retrospective immunohistochemical study.  Breast J. 2007 March-April;13(2):130-139.

Lo KC, Rossi MR, LaDucca J, Hicks DG, Turpaz Y, Hawthorn L, Cowell JK.  Candidate

glioblastoma development gene identification using concordance between copy number abnormalities as defined by array comparative genomic hybridization and gene expression levels.  Genes Chromosomes Cancer. 2007 October;46(10):875-894.

Amend K, Hicks DG, Ambrosone CB.  Breast cancer in African-American women: differences in tumor biology from European-Americans.  Cancer Res. 2006 September;66(17):8327-8330.

Hicks DG, Yoder BJ, Short S, Tarr S, Prescott N, Crowe JP, Dawson AE, Budd GT, Sizemore S, Muzaffern C, Choueriri T, Tubbs R, Gail D, Nowak N, Accavitti-Loper M, Frost AR, Welch D, Casey G.  Loss of breast cancer metastasis suppressor 1 protein expression predicts reduced disease-free survival in subsets of breast cancer patients.  Clin Cancer Res. 2006 November;12(22):6702-6708.

Shao YY, Wang L, Hicks DG, Ballock RT.  Analysis of gene expression in mineralized skeletal tissues by laser capture microdissection and RT-PCR.  Lab Invest. 2006 October;86(10):1089-1095.

Hicks DG, Short SM, Prescott NL, Tarr SM, Coleman KA, Yoder BJ, Crowe JP, Choueiri TK, Dawson AE, Budd GT, Tubbs RR, Casey G, Weil R.  Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6 and over-express HER2 or EGFR.  Am J Surg Pathol. 2006 September;30(9):1097-1104.

Crowe JP, Patrick RJ, Rybicki LA, Budd GT, Escobar PF, Tubbs RR, Hicks DG.  HER2 status in bilateral breast cancer.  Int J Fertil Womens Med. 2006 September-October;51(5):219-223.

Crowe JP, Patrick RJ, Rybicki LA, Escobar PF, Weng D, Budd T, Tubbs RR, Procop GW, Hicks DG.  A data model to predict HER2 status in breast cancer based on the clinical and pathologic profiles of a large patient population at a single institution.  Breast. 2006 December;15(6):728-735.

Ring BZ, Seitz RS, Beck R, Shasteen WJ, Tarr SM, Cheang MCU, Yoder BJ, Budd GT, Nielsen TO, Hicks DG, Estopinal NC, Ross DT.  A novel prognostic immuno-histochemical biomarker panel for estrogen receptor-positive breast cancer. J Clin Oncol. 2006 July;24(19):3039-3047. 

Haka AS, Volynskaya Z, Gardecki JA, Nazemi J, Lyons J, Hicks D, Fitzmaurice M, Dasari RR, Crowe J, Feld MS. In Vivo margin assessment during partial mastectomy breast surgery using Raman spectroscopy. Cancer Res. 2006 March;66(6):3317-3322.

Chow WA, Bedell V, Gaytan P, Borden E, Goldblum J, Hicks D, Slovak ML.  Methylthioadenosine phosphorylase gene deletions are frequently detected by fluorescence-in-situ hybridization in conventional chondrosarcomas.  Cancer Genet Cytogenet. 2006 April;15(2):95-100.

Escobar PF, Patrick RJ, Rybicki LA, Hicks DG, Weng D, Crowe JP.  Prognostic significance of residual breast disease and axillary node involvement for patients who had primary induction chemotherapy for advanced breast cancer.  Ann Surg Oncol. 2006 June;13(6):783-787.

Downs-Kelly E, Yoder BJ, Stoler M, Tubbs RR, Skacel M, Grogan T, Roche P, Hicks, DG.  The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in-situ hybridization (FISH), immunohistochemical (IHC) and isotopic mRNA in-situ hybridization study.  Am J Surg Pathol. 2005 September;29(9):1221-1227.

Shao YY, Wang L, Hicks DG, Tarr S, Ballock RT.  Expression and activation of peroxisome proliferator activated receptor in growth plate chondrocytes.  J Orthop Res. 2005 September;23(5):1139-1145.

Hicks, DG, Yoder BJ, Pettay J, Swain E, Tarr S, Hartke M, Skacel M, Crowe JP, Budd GT and Tubb RR. Incidence of Topoisomerase II-alpha (TOP2A) Genomic Alterations in Adenocarcinoma of the Breast and Their Relationship to HER2 Gene Amplification: A Flourescence In Situ Hybridization Study.  Hum Pathol. 2005 April;36(4):348-356.

Hicks DG, Tubbs RR.  Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization (FISH): A technical review with interpretive guidelines. Hum Pathol. 2005 March;36(3):250-261.

Yoder BJ, Tso E, Skacel M, Pettay J, Tarr S, Budd T, Tubbs RR, Adams JC, Hicks DG.  The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical course.  Clin Cancer Res 2005 January;11(1):186-192.

Downs-Kelly E, Pettay J, Hicks DG, Skacel M, Yoder BJ, Myles J, Screenan J, Roche P, Powell R, Hainfeld J, Grogan T, Tubbs R.  Analytical validation and interobserver reproducibility of SILVERFISH: A second generation bright field metallography assay for concomitant detection of HER2 gene status and protein expression in invasive carcinoma of the breast.  Am J Surg Pathol. 2005 November;29(11):1505-1511.

Hicks DG, Farver C, Goss G, Goldblum JR.  Harvesting major gains in histopathology and anatomic pathology: The Cleveland Clinic experience. The Bulletin of the Royal College of Pathologists. 2004;128:28-31.

Ritchlin CT, Haas-Smith SA, Ping L, Hicks DG, and Schwarz EM.  Mechanisms of TNF-α and RANKL mediated osteoclastogenesis and bone resorption in sporiatic arthritis. J Clin Invest. 2003 March;111(6):821-831.